Evidence map›Paper›PMID 35049127›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2022

Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia.

Sylvie Belleville, Simon Cloutier, Samira Mellah, Sherry Willis, Bruno Vellas, Sandrine Andrieu, Nicola Coley, Tiia Ngandu, MAPT/DSA group

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Nutrition: A non-negligible factor in the pathogenesis and treatment of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 5 countries.

Sylvie BellevilleResearch Center, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada.
Simon CloutierResearch Center, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada.
Samira MellahResearch Center, Institut Universitaire de gériatrie de Montréal, Montreal, Quebec, Canada.
Sherry WillisDepartment of Psychiatry, University of Washington, Seattle, Washington, USA.
Bruno VellasGérontopôle de Toulouse, CHU de Toulouse, Toulouse, France.
Sandrine AndrieuCenter for Epidemiology and Research in Population health (CERPOP), University of Toulouse, Toulouse, France.
Nicola ColeyCenter for Epidemiology and Research in Population health (CERPOP), University of Toulouse, Toulouse, France.
Tiia NganduDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
MAPT/DSA group
Inserm · FRInstitut Universitaire de Gériatrie de Montréal · CAApple (Israel) · ILFinnish Institute for Health and Welfare · FIUniversité de Montréal · CAUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversity of Washington · US

Funding

CIHR
6 · The paper itself

Abstract

backgroundLittle is known regarding the dose-response function in multidomain interventions for dementia prevention.

methodThe Multidomain Alzheimer Preventive Trial is a 3-year randomized controlled trial comprising cognitive training, physical activity, nutrition, and omega-3 polyunsaturated fatty acids for at-risk older adults. The dose delivered (number of sessions attended) was modeled against global cognition, memory, and fluency in 749 participants. Interaction effects were assessed for age, sex, education, dementia score (CAIDE), frailty score, and apolipoprotein E (APOE) ε4 status.

resultsThe dose-response models were non-linear functions indicating benefits up to about 12 to 14 training hours or 15 to 20 multidomain sessions followed by a plateau. Participants who benefited from a higher dose included women, younger participants, frail individuals, and those with lower education or lower risk of dementia. DISCUSSION: The non-linear function indicates that a higher dose is not necessarily better in multidomain interventions. The optimal dose was about half of the potentially available sessions.

Indexed as

Alzheimer DiseaseCognition DisordersFatty Acids, Omega-3AgedApolipoprotein E4CognitionExerciseFemaleHumansMaleApolipoprotein E4Fatty Acids, Omega-3cognitive agingcognitive declinecognitive trainingdementiadosagedose-responseinterventionmultidomainprevention

Identifiers

PMID35049127
PMCPMC9786573
OpenAlexW4205299597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.